Angiotensin receptor blocker may improve outcomes in nonobese COVID-19 patients
Use of the angiotensin receptor blocker candesartan appears to confer benefits for length of hospital stay, radiological outcome, and time-to-negative swab in the subgroup of nonobese patients with COVID-19, according to a study.